ADC Therapeutics' LOTIS-5 Setback Forces a Pivot to LOTIS-7 as the Stock Craters 73%

FDA raises benefit/risk concerns on the confirmatory trial; the company doubles down on the glofitamab combination and cuts costs.

ADCT · Earnings Call · 2026-08-13

A Regulatory Crossroads

ADC Therapeutics (ADCT) entered Q2 2026 with its fortunes pinned to two pivotal trials, but the quarter ended with one of them in doubt. On the earnings call, CEO Ameet Mallik confirmed that the FDA, following a pre-sBLA meeting, had “noted substantial concerns regarding the benefit risk or verification of clinical benefit observed in the LOTIS-5 trial.” — Ameet Mallik, Chief Executive Officer · 2026-08-13 This is a stark reversal from the company's own confidence earlier in the year, when management reaffirmed that a positive PFS readout would drive a mid-2027 approval. The stock has since collapsed 73% in the last 90 days, a sharp repricing of the asset's regulatory future. Crucially, the FDA's concerns were isolated to the combination of ZYNLONTA plus rituximab. As Mallik clarified, “There was no feedback at all about the single agent.” — Ameet Mallik, Chief Executive Officer · 2026-08-13 The accelerated approval for third-line plus DLBCL remains intact, which is why the commercial franchise continues to post stable, if unexciting, revenues. Yet the setback reshapes the bull case: LOTIS-5 was the vehicle for full approval and the $200–300 million second-line opportunity. Now that path is muddied.

The LOTIS-7 Pivot

In parallel, the company is repositioning its hopes on LOTIS 7 data — the Phase Ib combination of ZYNLONTA with the bispecific glofitamab. Enrollment of 100 patients at the selected dose is complete, and the data have been submitted to ASH. Mallik was unequivocal: “We do believe that we have very compelling data, both from an efficacy and a safety standpoint within the LOTIS-7 data.” — Ameet Mallik, Chief Executive Officer · 2026-08-13 The company plans to file for breakthrough designation this year and is actively exploring a Phase III path, with the goal of taking a leading second line position in DLBCL. This is a deliberate strategic pivot. In November 2025, management had already highlighted the potential of the combination, but the language has shifted from cautious optimism to a conviction that it can be practice-changing. The safety profile is a key differentiator: the LOTIS-7 protocol includes prophylactic measures for infections, which the company believes contributed to the lower rate of serious bacterial events compared to LOTIS-5. As Mallik explained when asked about the Grade 5 infections, “The primary type of infections were bacterial, which is why we think that prophylaxis could play a role.” — Ameet Mallik, Chief Executive Officer · 2026-08-13

Right now, we're basically going through the feedback and assessing whether additional data risk management options or modification to the potential label can help to address those FDA concerns.
Ameet Mallik, Chief Executive Officer · 2026-08-13

Even with this pivot, the market remains skeptical. The 73% drawdown suggests investors see the LOTIS-5 failure as a fundamental dent in the franchise's total addressable opportunity, and the LOTIS-7 path is longer, unproven, and dependent on a partner (Roche, which supplies glofitamab) and a new Phase III design.

Cost Cuts and a Longer Runway

To fortify the balance sheet, management announced a strategic reorganization in June, including a 17% workforce reduction and an additional $10 million in annualized savings. CFO Jose Carmona reported that Q2 non-GAAP operating expenses fell 22% year-over-year, and the company ended the quarter with $219.1 million in cash, enough to fund operations into 2028. The cost discipline is visible in the fundamentals: Research and development expenses have declined from a peak of $38M in Q1 2023 to $20M in Q1 2026, reflecting the reprioritization of the clinical portfolio. Yet the commercial trajectory remains tepid. ZYNLONTA net product revenues were $18.6M in Q2 2026, roughly flat with the prior year, and the company has repeatedly framed sales as “broadly in line with recent quarters.” — Operator · 2026-08-13 In the November 2025 call, Mallik had projected the real inflection point would come with LOTIS-5 approval: “The real inflection point will start when we get the approval for LOTIS-5 next year where we think we can really significantly increase the potential sales opportunity.” — Ameet Mallik, Chief Executive Officer · 2026-03-10 That inflection now looks delayed at best.

What Changed, and Why It Matters

Before this quarter, the company's own keyword trajectory was dominated by LOTIS 5, regulatory approval, and second-line expansion. Now the emphasis has shifted to compendia submission and breakthrough designation for LOTIS-7 and indolent lymphomas. The strategic reorganization is new, and the benefit risk concern is a fresh, company-unique threat. The net effect is a company in transition: it still has an approved product and a cash runway, but its primary growth engine — the confirmatory trial — is beset by regulatory uncertainty. For investors, the question is whether LOTIS-7 can truly deliver. The data so far are compelling, but the regulatory pathway is undefined, and the stock has voted with its feet. This is a classic binary-risk situation: if the company can navigate the FDA’s concerns on LOTIS-5 or win breakthrough designation for LOTIS-7, there is substantial upside from these levels; if not, the cash burn continues against a flat commercial base. The next 12 months will be decisive.